Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer

Context. Anaplastic thyroid cancer (ATC) is an aggressive tumor with a median survival of 3 to 9 months, a 1-year survival of less than 10% and without definitive therapies. Recently, in BRAF V600E mutated ATCs, new targeted therapy using a combination of a BRAF inhibitor, dabrafenib (Dab), with a m...

Descripción completa

Detalles Bibliográficos
Autores principales: Fazeli, Sasan, Paal, Edina, Maxwell, Jessica H., Burman, Kenneth D., Nylen, Eric S., Khosla, Shikha G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880026/
https://www.ncbi.nlm.nih.gov/pubmed/31766881
http://dx.doi.org/10.1177/2324709619890942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880026/
https://www.ncbi.nlm.nih.gov/pubmed/31766881
http://dx.doi.org/10.1177/2324709619890942

Ejemplares similares